REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Research/Highlighting the potential of GLP1-RA as an effective treatment for weight regain following bariatric surgery and discussing its implications for clinical practice.
Back to Research Library
GLP1-RALiraglutideSemaglutide

Highlighting the potential of GLP1-RA as an effective treatment for weight regain following bariatric surgery and discussing its implications for clinical practice.

May 17, 2026
Share

Source Paper

Efficacy of the Glucagon-Like Peptide-1 Receptor Agonists Liraglutide and Semaglutide for the Treatment of Weight Regain After Bariatric surgery: a Retrospective Observational Study.

Jensen Anders Boisen et al.Obesity surgery2023
Emerging Research

Based on emerging research. These findings are promising but require further validation.

About This Analysis

This article breaks down the findings from the source paper above into accessible language for the peptide research community. Our goal is to highlight what matters most — the practical implications, the strength of the evidence, and what it means for ongoing research.

GLP-1 Receptor Agonists Show Promise in Tackling Weight Regain After Bariatric Surgery

Published: May 17, 2026 | Source: Obesity surgery (2023) | Category: GLP1-RA, Liraglutide, Semaglutide

Overview

A recent study published in Obesity Surgery suggests that glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as liraglutide and semaglutide, can help patients who have regained weight after bariatric surgery to lose a significant portion of the regained weight within six months. This finding is crucial for those seeking effective treatments for weight regain following surgical interventions.

Study Background

Weight regain after bariatric surgery is a common issue, affecting up to one-third of patients. While GLP-1 RAs are known to be effective in managing type 2 diabetes and obesity, their role in treating weight regain specifically after bariatric surgery was less clear until now. This retrospective observational study aimed to fill this knowledge gap by examining the efficacy of liraglutide and semaglutide for patients who had regained weight post-surgery.

What the Research Found

The study involved 50 patients (82% female) at a Swiss bariatric reference center, with an average age of 47 years. Before treatment with GLP-1 RAs, these patients had an average body weight of 90.5 kg and a BMI of 34.0 kg/m². After six months of treatment (liraglutide: n=29; semaglutide: n=21), the median weight loss was substantial, with two-thirds of the regained weight being lost.

What This Means for Peptide Users

For individuals who have experienced weight regain after bariatric surgery, this study provides hope and a new therapeutic option. GLP-1 RAs can be an effective tool in helping these patients achieve significant weight loss, thereby improving their overall health outcomes and reducing the risk of obesity-related complications.

Limitations and Caveats

While promising, this study has several limitations that must be acknowledged. It was conducted at a single center with a relatively small sample size, which limits its generalizability to broader populations. Additionally, the retrospective nature of the research means there could be uncontrolled variables influencing the results. Randomized controlled trials are needed to confirm these findings and establish GLP-1 RAs as standard treatment options for weight regain after bariatric surgery.

How This Compares to Previous Research

Previous studies have highlighted the efficacy of GLP-1 RAs in treating obesity and type 2 diabetes, but this is one of the first to focus specifically on their role in managing weight regain post-bariatric surgery. The results align with earlier research showing that these peptides can induce significant weight loss, although the specific context of bariatric surgery adds a new dimension to our understanding.

Our Analysis

PeptideVault views this study as an important step forward in addressing the challenges faced by patients who experience weight regain after bariatric surgery. The findings are encouraging and provide a basis for further research. However, due to the limitations mentioned, it is crucial that future studies employ randomized controlled trial designs to validate these results.

Key Takeaways

  • GLP-1 RAs can help patients lose significant amounts of regained weight within six months after bariatric surgery.
  • The study highlights a need for larger-scale clinical trials to confirm the efficacy and safety of GLP-1 RAs in this specific patient population.
  • For now, healthcare providers should consider these findings as part of an evolving understanding of GLP-1 RA's potential benefits beyond traditional indications like diabetes and obesity.

Original Source

Citation: Jensen Anders Boisen, Renström Frida, Aczél Stefan et al. (2023). Efficacy of the Glucagon-Like Peptide-1 Receptor Agonists Liraglutide and Semaglutide for the Treatment of Weight Regain After Bariatric surgery: a Retrospective Observational Study.. Obesity surgery. DOI: 10.1007/s11695-023-06484-8

Access: https://pubmed.ncbi.nlm.nih.gov/36765019/

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

Editor's Note

This analysis was prepared by the Peptide Contacts research team. We encourage readers to review the full source paper for complete methodology and data. The original publication is available on PubMed.

Related Research

Highlighting the groundbreaking potential of semaglutide in preventing major adverse cardiovascular events among patients with obesity and existing cardiovascular disease.

SemaglutideGLP-1 receptor agonist

Comments

Sign in to join the discussion

This analysis is generated from peer-reviewed research for educational purposes only. It does not constitute medical advice. Always consult a qualified healthcare provider before using any peptide-based therapy.